Akums Drugs & Pharmaceuticals announced that all manufacturing operations at the affected sites of the company and its subsidiaries, situated in the state of Uttarakhand, have been successfully resumed at 100% operations capacity with effect from 18 May 2026. According to the company's regulatory disclosure filed by Dharamvir Malik, Company Secretary & Compliance Officer, this marks the complete restoration of production capabilities at the Haridwar facilities after a temporary disruption caused by industry-wide labour unrest. The swift resumption demonstrates the company's operational resilience and ability to quickly restore normal production levels.
The partial disruption in production at Haridwar sites lasted for four days, resulting in a ₹20 crore supply backlog. As reported by the company's regulatory filing, this production halt had created supply chain challenges for the pharmaceutical company's operations in the region. However, the company expressed hope to make up for the production loss in the coming weeks, demonstrating confidence in its operational recovery capabilities. Market analysts consider this impact as a manageable fraction of the company's annual revenue scale, with the ₹20 crore delay representing a recoverable operational blip given Akums' large annual revenue base.
The disruption originated on May 14, 2026, as part of an industry-wide labour unrest triggered by minimum wage review by state authorities. According to the company's disclosure, this labour unrest affected all major industrial towns and manufacturing facilities across the state of Uttarakhand, not being limited to the pharmaceutical sector alone. Operations at other manufacturing units and locations of the company remained stable and continued as usual throughout the period of disruption, with local authorities actively coordinating with industries to restore normalcy. The specific cause of the disruption was not detailed in the brief, but the resumption of full operations within four days suggests it was likely a temporary technical or utility disruption rather than a structural or regulatory issue.
The company has now successfully restored all manufacturing operations to full capacity at its Uttarakhand facilities. According to the regulatory filing, there is no damage to the property of the company, consequently no insurance claim will be made for the said disruption of operation. The actual amount of damage has not yet been ascertained, and the company has assured stakeholders that further updates regarding the situation and its material impact, if any, will be provided in due course. Market analysts expect the immediate impact on the stock to be neutral as the resumption news offsets the delay quantification, with the ₹20 crore delay being a one-time event with minimal impact on FY27 EBITDA projections.
